NetworkNewsWire Editorial Coverage: With cannabis set to become legal for recreational use in July 2018 in Canada, and usage of the product for medical purposes steadily rising both in Canada and worldwide, cannabis companies have ramped up their efforts to make new scientific discoveries related to the plant’s medical uses. Companies leading the quest to demonstrate the potential of cannabis in a medicinal context are
Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) (VRTHF Profile), GW Pharmaceuticals (NASDAQ: GWPH), Canopy Growth Corp. (OTC: TWMJF) (TSX: WEED), Aphria, Inc. (OTCQB: APHQF) (TSX: APH) and
Aurora Cannabis, Inc. (OTCQX: ACBFF) (TSX: ACB).
Among companies seeking to produce clinical data to validate medical marijuana claims,
Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) has carved its own niche with a multi-front approach to identifying the potential of its cannabis products for ameliorating a variety of maladies, including pain, nausea, epilepsy and PTSD.
Read the full article
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:
http://NNW.fm/Disclaimer
